

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

violetFluor 450 Anti-Mouse CD45 (30-F11)

RRID:AB_2621947

Type: Antibody

Proper Citation

Tonbo Biosciences Cat# 75-0451, RRID:AB_2621947

Antibody Information

URL: http://antibodyregistry.org/AB_2621947

Proper Citation: Tonbo Biosciences Cat# 75-0451, RRID:AB_2621947

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Original manufacturer of this product; Applications: FC Dilution: This antibody preparation has been quality-tested for flow cytometry using mouse spleen cells, or an appropriate cell type (where indicated). Please refer to the figure legend for the optimal concentration used to stain the tissue shown. We recommend titrating the antibody under your specific conditions to determine the optimal concentration of antibody needed in your experimental system.

Antibody Name: violetFluor 450 Anti-Mouse CD45 (30-F11)

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: 30-F11

Antibody ID: AB_2621947

Vendor: Tonbo Biosciences

Catalog Number: 75-0451

Alternative Catalog Numbers: OWL-A12219

Record Creation Time: 20231110T034843+0000

Ratings and Alerts

No rating or validation information has been found for violetFluor 450 Anti-Mouse CD45 (30-F11).

No alerts have been found for violetFluor 450 Anti-Mouse CD45 (30-F11).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xu Z, et al. (2026) Unbiased niche labeling maps immune-excluded niche in bone metastasis. *Cell*, 189(11), 3287.

Alam R, et al. (2025) Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2-Breast Cancer. *Cancer discovery*, 15(4), 818.

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. *Cancer cell*, 43(5), 823.

Yu L, et al. (2025) Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. *Immunity*, 58(4), 909.

Vardam-Kaur T, et al. (2024) The ATP-exporting channel Pannexin 1 promotes CD8+ T cell effector and memory responses. *iScience*, 27(7), 110290.

McGinnis CS, et al. (2024) The temporal progression of lung immune remodeling during breast cancer metastasis. *Cancer cell*, 42(6), 1018.

Zhang W, et al. (2023) Bone Metastasis Initiation Is Coupled with Bone Remodeling through Osteogenic Differentiation of NG2+ Cells. *Cancer discovery*, 13(2), 474.

Hao X, et al. (2023) Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. *Cell stem cell*, 30(5), 648.

Pingili AK, et al. (2021) Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. *Cell reports*, 35(12), 109285.

Fiege JK, et al. (2021) Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. *Cell host & microbe*, 29(12), 1815.

Liu X, et al. (2021) Notch-induced endoplasmic reticulum-associated degradation governs mouse thymocyte γ -selection. *eLife*, 10.

Stephens WZ, et al. (2021) Epithelial-myeloid exchange of MHC class II constrains immunity and microbiota composition. *Cell reports*, 37(5), 109916.

Kasitinon SY, et al. (2019) TRPML1 Promotes Protein Homeostasis in Melanoma Cells by Negatively Regulating MAPK and mTORC1 Signaling. *Cell reports*, 28(9), 2293.